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More than 50 000 implantable cardioverter-defibrillators (ICDs) are inserted annually in patients aged ≥65,1,2 
with >40% of ICDs placed in patients aged ≥70 years and 
>10% in patients ≥80.1 As guidelines and systematic reviews 
explicitly discourage use of age alone as an exclusion for ICD 
implantation,3,4 demographic trends and the growing burden 
of heart disease will make millions more older patients eli-
gible for these devices in the coming years.5 Moreover, older 
patients receiving ICDs are at higher risk for short-term death, 
in comparison with younger patients,6 and face other impor-
tant uncertainties regarding their clinical course and health-
care needs after implantation.7
Clinical Perspective on p 2037
One of the most challenging healthcare transitions for 
older patients is hospice enrollment, because this represents a 
shift in the primary goal of care from survival to comfort and 
generally signifies that the end of life is approaching. Although 
Background—Older recipients of implantable cardioverter-defibrillators (ICDs) are at increased risk for short-term mortality 
in comparison with younger patients. Although hospice use is common among decedents aged >65, its use among older 
ICD recipients is unknown.
Methods and Results—Medicare patients aged >65 matched to data in the National Cardiovascular Data Registry – ICD 
Registry from January 1, 2006 to March 31, 2010 were eligible for analysis (N=194 969). The proportion of ICD 
recipients enrolled in hospice, cumulative incidence of hospice admission, and factors associated with time to hospice 
enrollment were evaluated. Five years after device implantation, 50.9% of patients were either deceased or in hospice. 
Among decedents, 36.8% received hospice services. The cumulative incidence of hospice enrollment, accounting for 
the competing risk of death, was 4.7% (95% confidence interval [CI], 4.6%–4.8%) within 1 year and 21.3% (95% CI, 
20.7%–21.8%) at 5 years. Factors most strongly associated with shorter time to hospice enrollment were older age 
(adjusted hazard ratio, 1.77; 95% CI, 1.73–1.81), class IV heart failure (versus class I; adjusted hazard ratio, 1.79; 95% 
CI, 1.66–1.94); ejection fraction <20 (adjusted hazard ratio, 1.57; 95% CI, 1.48–1.67), and greater hospice use among 
decedents in the patients’ health referral region.
Conclusions—More than one-third of older patients dying with ICDs receive hospice care. Five years after implantation, 
half of older ICD recipients are either dead or in hospice. Hospice providers should be prepared for ICD patients, whose 
clinical trajectories and broader palliative care needs require greater focus.  (Circulation. 2016;133:2030-2037. DOI: 
10.1161/CIRCULATIONAHA.115.020677.)
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hospice is the main provider of end-of-life care in the United 
States,8 its use among patients with ICDs is unknown. Early 
work suggests that hospice providers may be ill prepared to 
address the unique end-of-life care needs of these patients. For 
example, 1 study found that only 10% of hospice providers 
have a device deactivation policy.9 At the same time, a lim-
ited number of small studies involving retrospective postdeath 
family interviews10 and patient and provider surveys11–13 sug-
gest that unwanted shocks, particularly near the end of life, 
contribute to pain, decreased quality of life, and patient and 
family distress.14,15
Despite the high mortality rate of older ICD patients, 
very little is known about the extent to which they currently 
access hospice services. Such information may help hospice 
providers better understand and prepare for their role in car-
ing for these patients, assist in targeting patients who have the 
greatest need for hospice care earlier in their clinical course, 
further inform patients and their families about their future 
care needs, and support shared decision making regarding 
initial implantation. To address these knowledge gaps, we 
leveraged data from National Cardiovascular Data Registry 
(NCDR) ICD Registry linked to Medicare claims to describe 
the incidence and features of hospice use in a large, nationally 
representative sample of older patients following ICD implan-
tation, and to identify factors associated with hospice enroll-
ment in this cohort.
Methods
Data Sources
This study analyzed data from the NCDR ICD Registry, the details 
of which have been previously published.16 In brief, this registry 
was established in 2005 in concert with the Centers for Medicare 
and Medicaid Services expansion of coverage for primary preven-
tion ICD implantation, with the goal of prospectively enrolling all 
Medicare beneficiaries receiving ICDs for primary prevention of 
sudden cardiac death as a condition of payment. Participating sites 
are trained on data collection, including the use of standardized 
definitions, and submitted data are subject to audit for errors and 
completeness.17 In practice, the majority of the >1500 participating 
hospitals enter data for all ICD recipients regardless of insurance 
status or indication.2,18
To ascertain hospice enrollment among ICD recipients, ICD 
Registry data for patients receiving implants between January 1, 
2006 and March 31, 2010 were combined with Medicare fee-for-
service hospice claims from January 1, 2006 to December 31, 2010, 
ensuring at least 9 months follow-up after device insertion. Indirect 
patient linkage was accomplished via a previously established algo-
rithm by using the following identifiers: age, sex, admission date or 
procedure date, and hospital Medicare provider number to achieve 
a 63% match rate.19 Death dates were derived from Centers for 
Medicare and Medicaid Services enrollment files and validated with 
data from the Social Security Administration. To assess regional 
variation in hospice referral after ICD placement, 2010 data from 
the Dartmouth Atlas were linked to the analytic file to character-
ize hospice use among decedents in the ICD patients’ hospital refer-
ral region (HRR). This year was selected because it was the only 
one corresponding to our study period for which these data were 
available.
The Yale University Human Investigation Committee and 
Institutional Review Boards at Beth Israel Deaconess Medical Center 
and Hebrew SeniorLife Institute for Aging Research approved the 
conduct of this study.
Study Population
Patients >65 years who had ICDs inserted between January 1, 2006 
through March 31, 2010 were eligible (Figure 1), aligned with use of 
the ICD Registry Version 1.0 collection form. Patients who were not 
fee-for-service Medicare patients were excluded because claims data 
for health maintenance organization enrollees were not available in 
the data files. There was no requirement for continuous fee-for-ser-
vice enrollment before the index procedure. Patients enrolled in hos-
pice before device placement were also excluded. For patients with 
multiple procedures during the study period, the first entry into the 
registry was taken as the index procedure for analytic purposes. Thus, 
baseline characteristics and time-to-event analyses are anchored to 
the index procedure, which may have been either a new or replace-
ment ICD insertion.
Patient Characteristics
Patient characteristics were derived from ICD Registry Data 
Collection Form v1.08 at the time of device placement unless oth-
erwise stated. Demographic variables included age, sex, and race 
(white, black, or other). Clinical information included cardiac con-
ditions, noncardiac conditions, diagnostic studies, and procedural 
details. Cardiac conditions, as documented in the standard ICD 
Registry form, included congestive heart failure, functional status 
(New York Heart Association class I–IV), atrial fibrillation/flutter, 
ventricular tachycardia, nonischemic cardiomyopathy, any ischemic 
heart disease, myocardial infarction, coronary artery bypass graft-
ing, percutaneous coronary intervention, previous ICD implantation, 
and cerebrovascular disease. We also included type of device (single 
chamber, dual chamber, or biventricular) and whether the device was 
for primary or secondary prevention. In the ICD Registry, second-
ary prevention indicates patients who have previously experienced 
sustained ventricular arrhythmias or, for those with an ICD implant 
before their index procedure in this cohort, appropriate ICD therapy. 
We also ascertained the most recent estimates of left ventricular 
ejection fraction (%) and glomerular filtration rate (mL/min), calcu-
lated using the Modification of Diet in Renal Disease Study Group 
(MDRD) Study.20 Noncardiac comorbidities abstracted from the ICD 
registry form included chronic lung disease, diabetes mellitus, and 
hypertension.
We postulated that dementia and cancer would be associated with 
hospice referral. Because these diagnoses are not included in the ICD 
Registry, these were obtained from International Classification of 
Figure 1. Derivation of study cohort. ICD indicates implantable 
cardioverter-defibrillator.
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Diseases, Ninth Revision codes on the Medicare claim associated with 
the index procedure. To construct the cancer and dementia variables, we 
used a modified version of the Hierarchical Condition Categories.21,22
Finally, Medicare claims data were used to determine whether 
subjects were admitted to a skilled nursing facility in the 6 months 
before the index ICD procedure.
Hospice Use
Whether or not a subject was enrolled in hospice following ICD 
placement was determined by using Medicare hospice claims. If the 
subject was enrolled, we determined the dates of admission and dis-
charge, length of stay, site of care (hospital versus home-based), and 
primary admitting diagnosis.
Hospice Use in HRR
Previous research has shown that regional penetration of hospice is 
highly associated with whether or not individual patients are enrolled 
in hospice. To account for this observation, the percentage of dece-
dents who were enrolled in hospice during the last 6 months of life in 
the HRRs in which the subjects had their ICD inserted was ascertained 
from the Dartmouth Atlas by using 2010 data. Based on its distribu-
tion, this variable was categorized into quartiles as follows: 19.3% to 
<41.0%, 41.0% to <47.8%, 47.8% to <54.3%, 54.3% to 70.3%.
Statistical Analysis
All baseline demographic data, clinical information, and procedural 
variables were described using frequencies for categorical variables 
and means (standard deviations) and medians (first to third quartiles) 
for continuous variables.
The proportion of subjects who enrolled in hospice and the 
median time from index procedure to hospice enrollment were cal-
culated. For subjects admitted to hospice, length of stay was evalu-
ated in days and other characteristics of the hospice admission were 
presented as proportions. Time from ICD implantation and time from 
hospice admission to death were calculated in years. Cumulative inci-
dence was calculated accounting for the competing risk of death for 
the time to hospice admission outcome.
Our primary analysis used time to hospice enrollment as mea-
sured from the date of ICD placement to date of first hospice enroll-
ment as the outcome. Subjects who were never enrolled in hospice or 
were disenrolled from Medicare fee-for-service were censored at the 
end of the follow-up period (December 31, 2010). Missing data for 
each independent variable was iteratively imputed by using the Fully 
Conditional Specification method of multiple imputation to create 10 
imputed data sets.23 For each data set, a proportional subdistribution 
hazards model that accounted for the competing risk of death was 
used to examine the association between the independent variables 
and time to hospice enrollment.24 Hazard ratios and their associated 
standard errors were aggregated by taking the average of the esti-
mates across 10 imputed data sets. Statistical inference was made 
based on the averaged aggregate estimates and standard errors using 
standard pooling rules for multiply imputed data.25
Independent variables were selected from the data set a priori as 
those that were presumed to be potentially associated with survival in 
ICD patients or hospice enrollment based on the literature26 and clini-
cal judgment. Candidate independent variables included age (per 10 
years), female sex, race (white versus nonwhite), congestive heart fail-
ure, New York Heart Association class (using class I as reference), his-
tory of atrial fibrillation/flutter, history of ventricular tachycardia (any), 
ischemic heart disease, cerebrovascular disease, replacement ICD, 
cardiac resynchronization therapy versus non–cardiac resynchroniza-
tion therapy device, chronic lung disease, diabetes mellitus, dementia, 
history of cancer, skilled nursing facility claim in previous 6 months, 
left ventricular ejection fraction category (<20%, 20%–39%, ≥40); glo-
merular filtration rate (per 10 U increment), and the proportion of dece-
dents who died in hospice in the patients’ HRR categorized in quartiles. 
Unadjusted analyses examined the association between each individual 
independent variable and time to hospice. Variables associated with 
time to hospice at a P value of <0.2 were entered in the multivariable 
proportional subdistribution hazards model. Hazard ratios and 95% 
confidence intervals (CIs) were generated from these analyses again 
using the average of the estimates across 10 imputed datasets.
Replacement ICD was considered a priori to be an independent 
variable that might introduce survivorship bias and interactions 
with other independent variables based on previous studies.27 Thus, 
a second model was fit evaluating replacement ICD combined with 
prespecified interaction terms including age, atrial fibrillation, ven-
tricular tachycardia, congestive heart failure, and left ventricular 
ejection fraction. This second model did not impact the observed 
relationships, and thus we present only the results of the main model.
All analyses were performed using SAS v9.4 (SAS Institute, 
Cary, NC).
Results
Baseline Characteristics
From the 516 147 patients entered into the ICD Registry dur-
ing the study period, 312 801 were eligible for probabilistic 
matching after exclusions for age <65, discharge date out-
side of the study period, duplicates or missing hospital infor-
mation (Figure 1). Only 624 (0.3%) patients were excluded 
because of previous hospice enrollment. Probabilistic match-
ing to Medicare data yielded a final analytic cohort of 194 969. 
Comparisons between matched and nonmatched patients 
according to demographic and clinical characteristics showed 
no significant differences. The median follow-up time for the 
final analytic cohort was 1.92 years (first to third quartile, 1.13–
2.97). During the 5-year follow-up period, a total of 52 990 
(27.1%) patient deaths were observed. The 1-year and 5-year 
incidences of mortality were 12.1% and 48.8%, respectively.
The demographic, cardiovascular, and noncardiovascular 
characteristics of the total cohort and stratified according to 
hospice enrollment are shown in Table 1. The overall cohort’s 
mean age was 75.5±6.4 years, 25.7% were female, and 89.6% 
were white. In terms of cardiovascular disease, the majority 
of patients had congestive heart failure (80.0%) and ischemic 
heart disease (73.5%), including previous coronary artery 
bypass grafting (42.6%) or percutaneous coronary interven-
tion (34.5%). Clinical arrhythmias were common, including 
atrial fibrillation (42%) and ventricular tachycardia (41.7%). 
A total of 29.7% had received a previous ICD, 46.6% had 
cardiac resynchronization therapy devices, and 79.0% of all 
implant devices were placed for primary prevention. Among 
noncardiac conditions, only 1.1% of patients had a diagnosis 
of dementia, and only 1.7% had a previous diagnosis of cancer.
Hospice Enrollment
A total of 22 336 patients (11.5%) were enrolled in hospice 
during the 5-year follow-up period. The cumulative incidence 
of hospice admission, accounting for the competing risk of 
death, was 4.7% (95% CI, 4.6%–4.8%) at 1 year and 21.3% 
(95% CI, 20.7%–21.8%) at 5 years (Figure 2). For those 
enrolled in hospice, the median time from ICD implantation 
to hospice enrollment was 1.3 years (first to third quartiles, 
0.57–2.3 years). A total of 36.8% of decedents received hos-
pice services. At 5 years follow-up, 50.9% patients had either 
died or been enrolled in hospice.
For subjects who were admitted to hospice, the median 
length of stay for their first hospice admission was 10 days 
(first to third quartiles, 4–36 days). Death was documented 
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for 87.7% of hospice enrollees, and 84.3% of hospice services 
were provided at home (versus inpatient). The most common 
primary admitting diagnoses were congestive heart failure or 
cardiomyopathy (38.5%) and other heart disease (15.2%). 
Among noncardiac conditions, cancer diagnoses (17.5%), 
chronic kidney disease or renal failure (6.3%), chronic 
obstructive pulmonary disease and bronchiectasis (4.6%), and 
acute cerebrovascular disease (2.6%) were most common.
Factors Associated With Time to Hospice 
Enrollment
Unadjusted and adjusted associations between baseline char-
acteristics and time to first hospice enrollment are shown in 
Table 2. In unadjusted analysis, all independent variables were 
associated with time to hospice enrollment and were entered 
into the multivariable model. All independent variables in 
the adjusted model remained significantly associated with 
the outcome, with the following factors being most strongly 
associated with a shorter time to hospice enrollment: can-
cer (adjusted hazard ratio [AHR], 2.04; 95% CI, 1.88–2.20), 
dementia (AHR, 1.93; 95% CI, 1.76–2.12), older age (AHR, 
1.77; 95% CI, 1.73–1.81), class IV heart failure (versus class 
I [referent]; AHR, 1.79; 95% CI, 1.66–1.94); left ventricu-
lar ejection fraction <20 (AHR, 1.57; 95% CI, 1.48–1.67), 
chronic lung disease (AHR, 1.40; 95% CI, 1.36–1.44), and 
greater regional hospice penetration.
Table 1. Observed Baseline Characteristics of Study Cohort at Time of ICD Implantation Overall and According 
to Enrollment in Hospice Services During Follow-up
Total Population 194 969 
(100%)
Enrolled in Hospice 
22 336 (11.5%)
Not Enrolled in Hospice 
172 633 (88.5%)
Demographics
  Age at implant, y, mean±SD 75.5±6.4 77.9±6.4 75.2±6.3
  Female sex, n (%) 50 110 (25.7) 5481 (24.5) 44 629 (25.9)
  White race, n (%) 174 359 (89.6) 20 175 (90.5) 154 184 (89.4)
Cardiovascular comorbidities, n (%)
  Congestive heart failure 155 976 (80.0) 19 307 (86.5) 136 669 (79.2)
  New York Heart Association class
   Class I 22 297 (11.5) 1633 (7.3) 20 664 (12.0)
   Class II 67 060 (34.4) 6359 (28.5) 60 701 (35.2)
   Class III 97 338 (50.0) 12 737 (57.1) 84 601 (49.1)
   Class IV 8008 (4.1) 1573 (7.1) 6435 (3.7)
  History of atrial fibrillation/flutter 82 463 (42.3) 11 120 (49.8) 71 343 (41.3)
  History of ventricular tachycardia 81 166 (41.7) 9761 (43.7) 71 405 (41.4)
  Ischemic heart disease 143 163 (73.5) 17 312 (77.5) 125 851 (72.9)
  Cerebrovascular disease 34 667 (17.8) 5127 (23) 29 540 (17.1)
  Previous implantable cardioverter-defibrillator 57 829 (29.7) 6933 (31) 50 896 (29.5)
  Cardiac resynchronization therapy 90 714 (46.6) 11 632 (52.1) 79 082 (45.9)
Noncardiac comorbidities
  Chronic lung disease 47 056 (24.1) 6906 (30.9) 40 150 (23.3)
  Diabetes mellitus 72 985 (37.4) 8987 (40.2) 63 998 (37.1)
  Dementia 2177 (1.1) 512 (2.3) 1665 (1.0)
  History of cancer 3314 (1.7) 712 (3.2) 2602 (1.5)
  Skilled nursing facility claim in previous 6 mo 8683 (4.5) 1677 (7.5) 7006 (4.1)
Diagnostic studies
  Left ventricular ejection fraction, n (%)
   <20 22 018 (12.0) 3448 (16.3) 18 570 (11.4)
   ≥20 to <40 138 338 (75.4) 15 715 (74.4) 122 623 (75.5)
   ≥40 23 220 (12.6) 1968 (9.3) 21 252 (13.1)
   Missing* 11 393 (5.8) 1205 (5.4) 10 188 (5.9)
  Glomerular filtration rate, mean±SD 55.8±21.5 49.7±21.9 56.6±21.3
ICD indicates implantable cardioverter-defibrillator; and SD, standard deviation.
*Left ventricular ejection fraction was the only variable present with missing data >0.4%.
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Discussion
This report from a nationwide sample provides the first com-
prehensive assessment of hospice use in older patients follow-
ing ICD implantation. After accounting for the competing risk 
of death, the cumulative incidence rate of hospice admission 
in the 5 years following ICD placement was 21%. This finding 
underscores the need for hospice providers to prepare to care 
for dying ICD patients, including establishing protocols for 
turning off such devices and avoiding shocks at the end of life. 
At the same time, 63% of decedents did not receive hospice 
care. This finding, coupled with the fact that, at 5 years post-
implantation, 51% of older ICD patients were either dead or in 
hospice, calls for a much greater understanding of the broader 
palliative care needs of older ICD patients and improved strat-
egies to deliver that care.
Hospice is the main provider of end-of-life care for older 
Americans, with nearly half of all Medicare decedents making 
use of hospice services in 2012.28 In 2007, it was estimated 
that 43% of Medicare decedents with cancer and 34% of those 
with severe cognitive impairment received at least 3 days of 
hospice services.29 Thus, based on our findings, patients dying 
with ICDs are relatively common users of hospice, with 37% 
of decedents receiving such services and a cumulative inci-
dence rate of enrollment over 5 years of 21% among those 
who had not already died. Nonetheless, hospices may be 
ill prepared to manage ICD patients, as indicated in a 2010 
nationwide survey of 900 hospice providers indicating that, 
although 97% admitted patients with ICDs, only 10% had 
an ICD deactivation policy.9 Development and use of such 
policies, including routinely querying new hospice enrollees 
about the presence of an ICD, could be a potential quality met-
ric for hospice providers.
The observation that half of older ICD recipients were 
either in hospice or deceased by 5 years postinsertion signals 
a critical need to better understand the palliative care needs of 
this vulnerable population. Very little is currently known about 
the clinical course of older ICD patients with respect to prog-
nosis, communication, participation in advance care–planning 
discussions, sources of suffering, family member burden, and 
quality of end-of-life care. One concerning study found 65% 
of ICD patients (n=125, only 3% in hospice) had shock thera-
pies active at the time of death, with 31% receiving shocks in 
the hours before death.15 Given that hospice has been shown 
to improve several key outcomes among dying patients,30–32 
including those with cardiac disease,33 it is reasonable to 
assume that the 63% of ICD decedents who did not receive 
hospice may have benefited from such services. Moreover, 
given that the median length of stay was only 10 days, in com-
parison with 17 days for all hospice recipients nationwide in 
2014,29 ICD patients who were enrolled in hospice may have 
benefited from earlier referral.
More broadly, the high mortality rate observed in our 
older ICD cohort, and the fact that the majority of decedents 
were never enrolled in hospice, suggests the need for greater 
integration of palliative care principles farther upstream in 
their clinical course. For example, general cardiologists and 
electrophysiologists should ensure that decision making at the 
time of device insertion is informed and aligned with patient 
preferences,34 and that such discussions are revisited in fol-
low-up as the patient’s clinical status evolves.35 Primary care 
providers should also actively address such issues, and general 
symptom management, as well, in the broader context of the 
patient’s comorbid conditions and overall status. Finally, spe-
cialized palliative consultation should be sought when needed, 
even if ongoing, potentially life-prolonging treatment, such as 
ICD use, is still desired.36
Our multivariable analysis identified several patient-level 
factors associated with time to hospice enrollment, particu-
larly previous diagnosis of cancer or dementia as well as age 
and severity of heart failure. Because these factors are also 
associated with greater mortality in these patients,26 their pres-
ence could help medical providers further refine patient selec-
tion for ICD implantation, and target those ICD patients who 
may particularly benefit from a more proactive palliative care 
approach or early hospice enrollment. Local market forces – 
as measured by the proportion of decedents in each patient’s 
Figure 2. Cumulative incidence (solid line) with 
95% confidence intervals (dashed lines) of hospice 
admission following implantable cardioverter-
defibrillator implantation.
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HRR – also emerged as strongly associated with our primary 
outcome. These findings are consistent with other studies of 
hospice use suggesting that the availability of providers and 
local clinical practice play important roles in the provision 
of hospice care, independent of clinical necessity or patient 
preferences.37
Our study has several potential limitations. Only ICD 
recipients in the ICD Registry who were matched to fee-for-
service Medicare claims were eligible for our analyses, and 
thus our findings may not extend simply to patients who are 
younger or those in managed care plans. Although our proba-
bilistic match strategy showed similar patient characteristics 
between matched and unmatched subjects, it is possible that 
residual differences remain between these groups. Follow-up 
ended in December 2010, and it is possible that hospice use 
among ICD recipients has evolved in the intervening years, 
although patient and market factors associated with hospice 
use have remained generally stable over time.18,38 Notably, 
access to palliative care more broadly has expanded mark-
edly in the years including and extending beyond our study 
period.39 Thus, it is possible that referral of ICD patients 
toward hospice care may in fact be even more common that 
what we identified. In evaluating factors associated with hos-
pice use, we were limited to variables ascertained from the 
Table 2. Unadjusted and Adjusted Associations Between Baseline Characteristics and Time to First Hospice Enrollment Following 
Implantable Cardioverter-Defibrillator Implantation
Variable
Unadjusted Hazard Ratio 
(95% Confidence Interval) P Value*
Adjusted† Hazard Ratio (95% 
Confidence Interval) P Value*
Age (per 10 y) 1.87 (1.83–1.92) <0.0001 1.77 (1.73–1.81) <0.0001
Female sex 0.94 (0.91–0.97) <0.001 0.93 (0.90–0.96) <0.0001
Race (white vs nonwhite) 1.08 (1.01–1.15) .02 0.94 (0.89–1.00) .05
Congestive heart failure 1.65 (1.59–1.72) <0.0001 1.21 (1.16–1.26) <0.0001
New York Heart Association class
  Class I 1.00 1.00
  Class II 1.32 (1.25–1.39) <0.0001 1.09 (1.03–1.15) <0.001
  Class III 1.83 (1.74–1.93) <0.0001 1.34 (1.26–1.43) <0.0001
  Class IV 2.68 (2.49–2.88) <0.0001 1.79 (1.66–1.94) <0.0001
History of atrial fibrillation/flutter 1.39 (1.35–1.43) <0.0001 1.17 (1.14–1.21) <0.0001
History of ventricular tachycardia 1.09 (1.06–1.12) <0.0001 1.09 (1.06–1.12) <0.0001
Ischemic heart disease 1.24 (1.20–1.29) <0.0001 1.11 (1.04–1.15) <0.0001
Cerebrovascular disease 1.41 (1.36–1.46) <0.0001 1.23 (1.19–1.28) <0.0001
Previous implantable cardioverter-defibrillator 1.20 (1.16–1.24) <0.0001 1.13 (1.09–1.17) <0.0001
Cardiac resynchronization therapy (CRT) vs non-CRT device 1.29 (1.26–1.33) <0.0001 0.94 (0.91–0.97) <0.001
Chronic lung disease 1.46 (1.41–1.50) <0.0001 1.40 (1.36–1.44) <0.0001
Diabetes mellitus 1.15 (1.12–1.19) <0.0001 1.14 (1.11–1.18) <0.0001
Dementia 2.33 (2.12–2.56) <0.0001 1.93 (1.76–2.12) <0.0001
History of cancer 2.04 (1.89–2.20) <0.0001 2.04 (1.88–2.20) <0.0001
Skilled nursing facility claim in previous 6 mo 1.88(1.78–1.98) <0.0001 1.45(1.36–1.53) <0.0001
Left ventricular ejection fraction
  <20 1.80 (1.70–1.91) <0.0001 1.57 (1.48–1.67) <0.0001
  ≥20 to <40 1.30 (1.24–1.36) <0.0001 1.18 (1.12–1.24) <0.0001
  ≥40 1.00 1.00
Glomerular filtration rate (per 10 U increment) 0.86 (0.86–0.87) <0.0001 0.91 (0.90–0.91) <0.0001
Quartile of % decedents in health referral region enrolled in hospice in last 6 mo of life
  Quartile I (19.3% to <41.0%) 1.00 1.00
  Quartile II (41.0% to <47.8%) 1.22 (1.14–1.30) <0.0001 1.25 (1.15–1.35) <0.0001
  Quartile III (47.8% to <54.3%) 1.46 (1.36–1.56) <0.0001 1.49 (1.38–1.62) <0.0001
  Quartile IV (54.3% to 70.3%) 1.78 (1.65–1.91) <0.0001 1.84 (1.70–1.99) <0.0001
*P values are 2-sided.
†Factors with unadjusted hazard ratios with P<0.2 were entered into the adjusted model.
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ICD Registry and Medicare claims. Factors potentially influ-
encing hospice use, such as patient preference and severity 
of comorbid conditions (eg, dementia), were not available. In 
addition, we characterized variables at the time of ICD implan-
tation, and were not able to account for interval development 
of conditions, such as cerebrovascular disease, progression 
of heart failure severity, or the incidence of ICD shocks. 
Characterizing these specific elements of patients’ evolution 
from healthy enough to receive an ICD to sick enough to merit 
hospice enrollment therefore remains a critical target of fur-
ther study. This is particularly urgent given the influence of 
ICDs themselves on patients’ likelihood of dying either sud-
denly or from a more progressive process, outcomes that may 
not align well with many older patients’ preferences.40
In summary, substantial numbers of ICD recipients use 
hospice services, yet with relatively short lengths of stay. 
Hospice providers should be prepared to manage the unique 
needs of these patients. In addition, the large portion of ICD 
patients who either died or were in hospice within 5 years of 
device implantation argues strongly that these patients, par-
ticularly those with advanced heart failure, may benefit from a 
palliative care approach earlier in their clinical course, includ-
ing earlier hospice referral. Finally, our study demonstrates a 
need for a clearer understanding of patients’ clinical trajecto-
ries following ICD implantation, including the ways in which 
these patients die, to provide the highest-quality care through-
out the entire experience of living and dying with an ICD.
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CLINICAL PERSPECTIVE
Although hospice is the main provider of end-of-life care in the United States, its use among patients with implantable 
cardioverter-defibrillators (ICDs) is unknown. This report leveraged data from National Cardiovascular Data Registry-ICD 
Registry linked to Medicare claims to describe the incidence and features of hospice use in a large, nationally representative 
sample of older patients following ICD implantation. Among 194 969 ICD recipients, after accounting for the competing 
risk of death, the cumulative incidence rate of hospice admission in the 5 years following ICD placement was 21%, with 
factors including cancer, dementia, older age, heart failure severity, and regional penetration of hospice care most strongly 
associated with a shorter time to hospice enrollment. Overall, our finding that substantial numbers of ICD recipients use 
hospice services underscores the need for hospice providers to prepare to care for dying ICD patients, including establishing 
protocols for identifying and turning off such devices and avoiding shocks at the end of life. At the same time, 63% of dece-
dents did not receive hospice care, and lengths of stay for hospice enrollment were relatively short. These findings, coupled 
with the fact that, at 5 years postimplantation, 51% of older ICD patients were either dead or in hospice, calls for a much 
greater understanding of the broader palliative care needs of older ICD patients and improved strategies to deliver that care.
